Contineum Therapeutics reported topline data from its Phase 2 VISTA trial of PIPE-307, an M1 receptor antagonist, for the treatment of relapsing-remitting multiple sclerosis (RRMS).
The trial demonstrated acceptable safety and tolerability at both doses but did not meet its primary or secondary efficacy endpoints.
No significant change was observed in binocular 2.5% low contrast letter acuity across treatment arms in RRMS patients.
Safety and Tolerability
PIPE-307 showed an acceptable safety and tolerability profile during the Phase 2 VISTA trial.
Efficacy Endpoints
The trial did not meet its prespecified primary or secondary efficacy endpoints for RRMS treatment.
Vision Acuity
No significant change in binocular 2.5% low contrast letter acuity was observed in RRMS patients receiving PIPE-307.
- Contineum Therapeutics expressed disappointment in the trial results but remains committed to developing novel therapies for inflammatory and fibrotic diseases.
- The Company will continue to analyze the trial data, especially related to exploratory endpoints, to extract insights for future developments.
Despite the trial results not meeting the expectations, Contineum Therapeutics remains dedicated to advancing therapies for patients with inflammatory and fibrotic diseases, aiming to learn and improve from the data obtained.